NASDAQ: ATHX |
| Healthcare / Biotechnology / USA |
0.7119 | -0.0104 | -1.44% | Vol 1.88M | 1Y Perf -56.22% |
May 18th, 2022 16:00 DELAYED |
BID | 0.6999 | ASK | 0.7500 | ||
Open | 0.7218 | Previous Close | 0.7223 | ||
Pre-Market | - | After-Market | 0.75 | ||
- - | 0.04 5.14% |
Target Price | 4.00 | Analyst Rating | Moderate Buy 2.00 | |
Potential % | 461.88 | Finscreener Ranking | + — - | |
Insiders Trans % 3/6/12 mo. | 100/100/-33 | Value Ranking | ☆ 23.59 | |
Insiders Value % 3/6/12 mo. | 100/100/-12 | Growth Ranking | ☆ 25.46 | |
Insiders Shares Cnt. % 3/6/12 mo. | 100/100/16 | Income Ranking | — - | |
Price Range Ratio 52W % | 18.60 | Earnings Rating | Buy | |
Market Cap | 183.72M | Earnings Date | 6th May 2022 | |
Alpha | 0.01 | Standard Deviation | 0.24 | |
Beta | -1.30 |
Today's Price Range 0.68000.7300 | 52W Range 0.46101.81 | 5 Year PE Ratio Range -6.40-7.20 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Buy |
Performance | |||
---|---|---|---|
1 Week | 24.28% | ||
1 Month | 42.44% | ||
3 Months | -15.91% | ||
6 Months | -36.08% | ||
1 Year | -56.22% | ||
3 Years | -63.34% | ||
5 Years | -49.84% | ||
10 Years | -46.89% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -155.87 | |||
ROE last 12 Months | -449.07 | |||
ROA (5Y Avg) | -70.67 | |||
ROA last 12 Months | -146.07 | |||
ROC (5Y Avg) | -149.81 | |||
ROC last 12 Months | -285.06 | |||
Return on invested Capital Q | -123.56 | |||
Return on invested Capital Y | -66.74 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 3.50 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-1.70 | ||||
478.33 | ||||
19.38 | ||||
- | ||||
-1.80 | ||||
-0.34 | ||||
478.33 | ||||
0.00 | ||||
134.57M | ||||
Forward PE | 0.68 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
0.90 | ||||
1.00 | ||||
0.97 | ||||
31.01 | ||||
- | ||||
Leverage Ratio | 3.30 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
-983.20 | ||||
-966.30 | ||||
-2 110.40 | ||||
- |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
8.43M | ||||
0.03 | ||||
-30.02 | ||||
2.51 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q01 2022 | - | -0.09 | - |
Q04 2021 | -0.07 | -0.09 | -28.57 |
Q03 2021 | -0.08 | -0.07 | 12.50 |
Q02 2021 | -0.08 | -0.10 | -25.00 |
Q01 2021 | -0.08 | -0.13 | -62.50 |
Q04 2020 | -0.09 | -0.11 | -22.22 |
Q03 2020 | -0.08 | -0.11 | -37.50 |
Q02 2020 | -0.08 | -0.10 | -25.00 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
12/2021 QR | -0.05 | 0.00 | - |
6/2022 QR | -0.09 | -132.14 | Negative |
12/2022 FY | 0.25 | -87.92 | Negative |
12/2023 FY | 0.85 | - | - |
Next Report Date | - |
Estimated EPS Next Report | - |
Estimates Count | - |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 1.88M |
Shares Outstanding | 258.07K |
Shares Float | 234.40M |
Trades Count | 6.54K |
Dollar Volume | 1.33M |
Avg. Volume | 2.97M |
Avg. Weekly Volume | 2.76M |
Avg. Monthly Volume | 3.20M |
Avg. Quarterly Volume | 2.95M |
Athersys Inc. (NASDAQ: ATHX) stock closed at 0.7223 per share at the end of the most recent trading day (a 11.45% change compared to the prior day closing price) with a volume of 2.08M shares and market capitalization of 183.72M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 83 people. Athersys Inc. CEO is William Lehmann.
The one-year performance of Athersys Inc. stock is -56.22%, while year-to-date (YTD) performance is -19.98%. ATHX stock has a five-year performance of -49.84%. Its 52-week range is between 0.461 and 1.81, which gives ATHX stock a 52-week price range ratio of 18.60%
Athersys Inc. currently has a PE ratio of -1.70, a price-to-book (PB) ratio of 478.33, a price-to-sale (PS) ratio of 19.38, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -146.07%, a ROC of -285.06% and a ROE of -449.07%. The company’s profit margin is -%, its EBITDA margin is -966.30%, and its revenue ttm is $8.43 Million , which makes it $0.03 revenue per share.
Of the last four earnings reports from Athersys Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Athersys Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Athersys Inc. is Moderate Buy (2), with a target price of $4, which is +461.88% compared to the current price. The earnings rating for Athersys Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Athersys Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Athersys Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 28.20, ATR14 : 0.09, CCI20 : 218.19, Chaikin Money Flow : -0.07, MACD : 0.01, Money Flow Index : 60.31, ROC : 47.38, RSI : 61.82, STOCH (14,3) : 94.43, STOCH RSI : 1.00, UO : 50.19, Williams %R : -5.57), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Athersys Inc. in the last 12-months were: Daniel A. Camardo (Buy at a value of $102 256), Ismail Kola (Buy at a value of $81 702), Ivor Macleod (Buy at a value of $17 706), John J. Harrington (Sold 47 874 shares of value $79 682 ), William Lehmann (Option Excercise at a value of $25 600), William Lehmann (Sold 120 000 shares of value $177 168 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Moderate Buy |
Athersys Inc is a clinical-stage biotechnology company. It is focused on developing novel and proprietary therapies in the areas where there is a significant unmet medical need, particularly in the regenerative medicine area. The firm's main product is Multistem cell therapy. Its current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.
CEO: William Lehmann
Telephone: +1 216 431-9900
Address: 3201 Carnegie Avenue, Cleveland 44115-2634, OH, US
Number of employees: 83
Wed, 16 Mar 2022 16:42 GMT Athersys (ATHX) Gets a Hold Rating from Bank of America Securities
- TipRanks. All rights reserved.Thu, 03 Feb 2022 13:10 GMT Analysts Offer Insights on Healthcare Companies: Athersys (ATHX) and Eli Lilly & Co (LLY)
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.